Cancer immunotherapy in patients with preexisting autoimmune disorders

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Cancer immunotherapy in patients with preexisting autoimmune disorders. / Donia, Marco; Pedersen, Magnus; Svane, Inge Marie.

I: Seminars in Immunopathology, Bind 39, Nr. 3, 04.2017, s. 333-337.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Donia, M, Pedersen, M & Svane, IM 2017, 'Cancer immunotherapy in patients with preexisting autoimmune disorders', Seminars in Immunopathology, bind 39, nr. 3, s. 333-337. https://doi.org/10.1007/s00281-016-0595-8

APA

Donia, M., Pedersen, M., & Svane, I. M. (2017). Cancer immunotherapy in patients with preexisting autoimmune disorders. Seminars in Immunopathology, 39(3), 333-337. https://doi.org/10.1007/s00281-016-0595-8

Vancouver

Donia M, Pedersen M, Svane IM. Cancer immunotherapy in patients with preexisting autoimmune disorders. Seminars in Immunopathology. 2017 apr.;39(3):333-337. https://doi.org/10.1007/s00281-016-0595-8

Author

Donia, Marco ; Pedersen, Magnus ; Svane, Inge Marie. / Cancer immunotherapy in patients with preexisting autoimmune disorders. I: Seminars in Immunopathology. 2017 ; Bind 39, Nr. 3. s. 333-337.

Bibtex

@article{c9c78c6689664ccbb43b8ba3ac17819b,
title = "Cancer immunotherapy in patients with preexisting autoimmune disorders",
abstract = "Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.",
keywords = "Antibodies, Monoclonal/adverse effects, Antineoplastic Agents/adverse effects, Autoimmune Diseases/complications, B7-H1 Antigen/antagonists & inhibitors, CTLA-4 Antigen/antagonists & inhibitors, Humans, Immune Tolerance, Immunosuppression, Immunotherapy/adverse effects, Molecular Targeted Therapy/adverse effects, Neoplasms/complications, Neoplasms, Second Primary/etiology, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Risk, Treatment Outcome",
author = "Marco Donia and Magnus Pedersen and Svane, {Inge Marie}",
year = "2017",
month = apr,
doi = "10.1007/s00281-016-0595-8",
language = "English",
volume = "39",
pages = "333--337",
journal = "Seminars in Immunopathology",
issn = "1863-2297",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Cancer immunotherapy in patients with preexisting autoimmune disorders

AU - Donia, Marco

AU - Pedersen, Magnus

AU - Svane, Inge Marie

PY - 2017/4

Y1 - 2017/4

N2 - Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.

AB - Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.

KW - Antibodies, Monoclonal/adverse effects

KW - Antineoplastic Agents/adverse effects

KW - Autoimmune Diseases/complications

KW - B7-H1 Antigen/antagonists & inhibitors

KW - CTLA-4 Antigen/antagonists & inhibitors

KW - Humans

KW - Immune Tolerance

KW - Immunosuppression

KW - Immunotherapy/adverse effects

KW - Molecular Targeted Therapy/adverse effects

KW - Neoplasms/complications

KW - Neoplasms, Second Primary/etiology

KW - Programmed Cell Death 1 Receptor/antagonists & inhibitors

KW - Risk

KW - Treatment Outcome

U2 - 10.1007/s00281-016-0595-8

DO - 10.1007/s00281-016-0595-8

M3 - Review

C2 - 27730287

VL - 39

SP - 333

EP - 337

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 3

ER -

ID: 195959089